Project Grant P01CA278716
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Institute of Dental and Craniofacial Research (NIDCR), through its Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $1,465,026 project grant to The University of Texas MD Anderson Cancer Center. The project, titled "HARVARD MD ANDERSON COLLABORATIVE TO REDUCE LYMPHATIC MORBIDITY IN HEAD AND NECK CANCER WITH ARTIFICIAL INTELLIGENCE (HARMONIC-AI)", aims to develop AI-powered tools to detect and manage post-treatment lymphedema and...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is providing $988,224 to the University of California, San Diego (UCSD) to advance the treatment of head and neck cancer patients with competing health risks through multi-center randomized clinical trials. The grant supports UCSD's role as a national leader in NRG Oncology, a National Clinical Trials Network, and the co-chair of the NCI Head and Neck Steering Committee. This funding...
- This $498,565 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for risk stratification and treatment optimization of locally advanced cervical cancer. The award aims to address the need for implementable biomarkers that can inform radiation therapy dosing decisions to balance toxicity and disease control, particularly in...
- The U.S. National Cancer Institute (NCI) awarded a $1,295,508 Project Grant to the Washington University in St. Louis on December 19, 2024 under the Cancer Treatment Research program (CFDA 93.395). The grant funds research to develop methods for suppressing the NRF2 transcription factor, which is overactive in over 30% of head and neck squamous cell carcinomas (HNSCC) and contributes to radiation therapy resistance. The research focuses on evaluating two novel NRF2 inhibitors, VVD065 and...
- This $2,896,024 federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a Virtual Preclinical CT (VPCT) platform for advanced imaging and theranostics in head and neck cancer research. The platform will integrate high-resolution photon-counting CT imaging with computational models to simulate tumor behavior, optimize imaging protocols, and evaluate therapeutic interventions in a virtual setting. Specific...
- The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) on July 2, 2025. The grant supports research aimed at developing a new therapy for aggressive diffuse-type gastric cancer (DGAC), which has limited treatment options and a poor prognosis. Key objectives include uncovering the mechanisms of DGAC tumorigenesis and identifying drug candidates that can target the root cells driving...
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.395 - Cancer Treatment Research to The University of Texas M.D. Anderson Cancer Center in the amount of $420,400.00 on August 1, 2025. The grant supports exploratory research to investigate cellular resistance mechanisms to MTA-cooperative PRMT5 inhibitors in MTAP-loss tumor cells. MTAP deletion occurs in approximately 15% of human malignancies, making these cancer cells particularly vulnerable to PRMT5 inhibition. The...
- The U.S. National Cancer Institute (NCI) awarded a $714,062 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of California, San Francisco (UCSF) for the period of April 15, 2025 to March 31, 2030. The grant aims to investigate the biological mechanisms contributing to racial disparities in head and neck cancer outcomes, particularly among Black patients. The key objectives are to: 1) Develop a tailored RNA prognostic model to enhance oral cancer survival...
- The University of Texas MD Anderson Cancer Center received a $513,127 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) to conduct research on the role of cancer pain-associated neuronal activity in driving malignancies. The award, with a project period from September 9, 2025 to August 31, 2030, will leverage preclinical models of malignant peripheral nerve sheath tumor (MPNST) to investigate how MPNST cells activate sensory...
- This $662,516 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital) to evaluate how fractionated radiation affects the tumor microenvironment and passive drug delivery in mouse and patient-derived models of locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The research aims to quantify the impact of local...